The latest analysis of the ORBITA-2 trial presented at the EuroPCR conference reveals that symptom relief, not the severity of coronary disease, is the key predictor of the benefit from PCI in stable angina patients. Patients with more typical angina symptoms are more likely to experience a reduction in angina following PCI, regardless of the anatomical severity of their disease. This new understanding challenges the traditional belief that relieving stenosis would relieve angina symptoms. The findings suggest a need for individualized screening of symptoms rather than focusing on disease severity to determine the appropriateness of PCI for stable angina patients.
Source link
PCI Benefit in Angina Clarified in New ORBITA-2 Analysis
